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Abstract
Background: Mycoplasma hyopneumoniae (Mhyo) and Porcine circovirus 2 (PCV-2) are two of the most significant
infectious agents causing economic losses in the weaning to slaughter period. Due to their similar vaccination age,
the objective of this study was to assess the efficacy of two already existing Mhyo (Hyogen®) and PCV-2 (Circovac®)
vaccines when administered separately or combined (RTM) by means of Mhyo or PCV-2 experimental challenges.
Results: Seven groups of animals were included in the study, being three of them challenged with PCV-2, three with
Mhyo and one composed of non-challenged, non-vaccinated pigs. Within each experimental challenge, non-vaccinated
(NV) groups were compared with double vaccinated groups using the commercial products separated (VS) or combined
(VC). Both vaccinated groups showed significant differences for most parameters measured regarding PCV-2 (serology,
percentage of infected animals and viral load in tissues) and Mhyo (serology and gross lesions) when compared to NV
groups. VS and VC offered similar results, being only significantly different the PCV-2 antibody values at different time
points (higher in the VS group) of the study, although not at the termination day (21 days post-PCV-2 inoculation).
Conclusion: The present study expands the knowledge on the possibility of using two separate Mhyo and PCV-2
commercial vaccines as a RTM product, which offered equivalent virological, immunological and pathological outcomes
as compared to these vaccines when used by separate.
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Background
Modern pig production sustainability, profitability and
efficiency mainly depend on the zootechnical perform-
ance of farms, which in turn is affected by animal health
and welfare [1]. Impairment of the health status, and in
consequence of the animal welfare, is usually multifac-
torial, with both infectious and non-infectious factors
able to exert detrimental effects.
Among infectious diseases, those causing respiratory
and systemic problems account for an important percent-
age of losses in pig farms [2]. Economic losses are mainly
attributed to mortality, growth retardation, medication as-
sociated costs and slaughter penalizations due to uneven
size of animals. Although the variety of infectious agents
linked to respiratory and systemic disorders is large, two
of the most significant ones are Mycoplasma hyopneumo-
niae (Mhyo) and Porcine circovirus 2 (PCV-2).
Besides, Mhyo is the etiological agent of enzootic pneu-
monia and PCV-2 the essential infectious cause for a group
of diseases named porcine circovirus diseases (PCVD) [3].
Indeed, both pathogens can be associated with the so-called
porcine respiratory disease complex (PRDC) [4]. PRDC is
clinically characterized by coughing, dyspnea, poor growth
and increased mortality [5]. Despite many other pathogens
can also participate in PRDC [6], prevention and control of
PCV-2 and Mhyo infections may represent corner-stones
to approach this multifactorial disorder. This scenario is
further emphasized by the fact that concomitant infections
with PCV-2 and Mhyo are frequently found under field
conditions [4] and a synergistic effect of both infections has
been demonstrated in certain experimental models [7, 8].
The most common practice to prevent Mhyo infections
is vaccination [9]. In fact, there is a high number of vaccine
products marketed worldwide [9, 10], which are mainly ap-
plied from the first week of life onwards. Infection due to
PCV-2 is almost uniquely prevented and controlled by
means of vaccination, being applied mostly around wean-
ing [11]. Although other interventions (biosecurity, diet,
stocking density, genetics and management) may partially
help in controlling PCVDs, PCV-2 vaccines offer the best
efficacy by far [11]. Taking into account that the infection
dynamics of both pathogens have some parallelisms (the
peak of infection usually occurs during the postweaning
period, although not necessarily concomitant), and that
vaccine application is usually in the piglet, the concept of
combined vaccination has been explored in the last 10
years. Such combined applications imply less handling
labour and, therefore, saving in management associated
costs. The first approach consisted of combining the two
already existing commercial vaccines from the same manu-
facturer in a ready-to-mix (RTM) strategy [12], but lately
ready-to-use (RTU) products have been developed and
reached the market [13, 14]. Therefore, the aim of the
present study was to assess the efficacy of two already
existing products in the market, Mhyo (Hyogen®) and
PCV-2 (Circovac®) vaccines, when administered separately
or combined (RTM) by means of Mhyo or PCV-2 experi-
mental challenges.
Results
Clinical signs and gross lesions
Four animals died before the end of the study. One ani-
mal from the VS (separate vaccination)-C (challenged)
Mhyo group died during blood sampling on SD (study
day) 0. Another one from the VC (combined vaccin-
ation)-C Mhyo group was euthanized on SD16 due to
welfare reasons. This latter animal lost body condition
and suffered from lameness of the left and right poster-
ior limbs (tarsus). At necropsy, this pig showed absence
of pulmonary collapse and mild increase of tarsal
articular fluid. A swab from this joint was obtained and
analysed by bacterial isolation without success. One ani-
mal from the VC-C PCV-2 group was found dead on
SD15. At necropsy, this pig had pleuritis and fibrin in
the thoracic cavity and yellowish fluid in the left anterior
limb joints (carpus and elbow). M. hyorhinis was de-
tected and cultured from swabs collected from joints.
And finally, one animal from the NV (non-vaccinated)-C
PCV-2 group was found dead (sudden death without
clinical signs) on SD16. At necropsy, this pig had blood-
stained liquid and fibrin in the abdominal and thoracic
cavities. Streptococcus suis was isolated in pure culture
from a peritoneal swab. All these animals were removed
from the study.
Body weight and ADWG
Mean body weight (±SD) and Average daily weight gain
(ADWG) (±SD) per treatment and time-point are detailed
in Table 1. No statistically significant differences neither
in body weight nor ADWG through the study were ob-
served between treatments in each challenge experiment.
PCV-2 results
Detection of antibodies against PCV-2
Mean Sample/Positive (S/P) ELISA values (±SD) per treat-
ment group and sampling point are represented in Fig. 1.
No statistically significant differences between treatment
groups in mean S/P enzyme-linked immunosorbent assays
(ELISA) values at the time of treatment distribution (data
not shown) and vaccination were found. From SD21 until
the end of the study, pigs from the VS-C PCV-2 group
showed significantly higher S/P values than NV-NC and
NV-C groups. VS-C PCV-2 group showed higher S/P
values than VC-C PCV-2 group, being these differences
statistically significant at SD21, SD41 SD70 and SD76.
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Detection and quantification of PCV-2 DNA
All animals included in the NV-NC group remained
quantitative real-time polymerase chain reaction
(QPCR) negative throughout the study. PCV-2 was
firstly detected at 7 days post-inoculation (dpi)
(SD70), where percentages of detection in all chal-
lenged groups were below 10% (Fig. 2). A higher
percentage of QPCR positive serum samples was observed
in the NV-C PCV-2 group at SD76 (9/14 [64,3%]) and
SD83 (11/14, [78,6%]) compared to VC-C PCV-2 (4/14
[28,6%] and 2/14 [14,3%], respectively) and VS-C PCV-2
(2/15 [13,4%] and 1/14 [6,7%], respectively) groups. These
differences, however, were only statistically significant on
SD83. No statistically significant differences were found
Table 1 Mean body weight (±SD) and mean ADWG (±SD) per treatment group
PCV-2 experiment
treatment groups
Body Weight (Kg) ADWG (Kg)
SD-5 SD62 SD83 ADWG SD5-SD62 ADWG SD62-SD83 ADWG SD5-SD83
NV-NC 3.80 ± 0.85 41.95 ± 8.75 63.43 ± 9.25 0.57 ± 0.12 1.02 ± 0.10 0.68 ± 0.10
NV-C PCV-2 3.81 ± 0.68 38.80 ± 6.31 60.61 ± 7.56 0.52 ± 0.09 1.04 ± 0.13 0.65 ± 0.08
VS-C PCV-2 3.69 ± 0,49 37.25 ± 6.16 56.96 ± 8,15 0.50 ± 0.09 0.94 ± 0.19 0.61 ± 0.09
VC-C PCV-2 3.65 ± 0.52 37.31 ± 4.27 57.61 ± 5.52 0.50 ± 0.06 0.97 ± 0.11 0.61 ± 0.06
Mhyo experiment
treatment groups
Body Weight (Kg) ADWG (Kg)
SD-5 SD62 SD91 ADWG SD5-SD62 ADWG SD62-SD91 ADWG SD5-SD91
NV-NC 3.80 ± 0.85 41.95 ± 8.75 70,22 ± 4.66 0.57 ± 0.12 1.05 ± 0.11 0.69 ± 0.05
NV-C Mhyo 3.77 ± 0.65 39.51 ± 4.96 66.09 ± 10.67 0.53 ± 0.07 0.92 ± 0.25 0.65 ± 0.11
VS-C Mhyo 3.77 ± 0.63 36.97 ± 4.30 64.48 ± 5.93 0.50 ± 0.06 0.95 ± 0.11 0.63 ± 0.06
VC-C Mhyo 3.81 ± 0.69 41.06 ± 4.86 70.33 ± 5.85 0.55 ± 0.06 1.01 ± 0.07 0.69 ± 0.06
Fig. 1 Mean (±SD) PCV-2 S/P ELISA values per treatment group and sampling point. Statistical differences are represented in the table below.
Different letters in superscript within a column means p < 0.05
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on percentage of PCV-2 QPCR pigs between vaccinated
groups at any sampling point.
PCV-2 viral load within QPCR positive samples
ranged from 1 × 104 to 5.26 × 105 copies/mL (Fig. 3).
No statistically significant differences on the mean
PCV-2 copies/mL of PCV-2 QPCR positive samples
was found between treatment groups at any sampling
point.
Animals from NV-C group had a numerically higher
area under the curve (AUC) (5.1) than animals from VC-C
PCV-2 (5.0) and VS-C PCV-2 (4.2) groups. These values
became statistically significant when all the animals (posi-
tive and negative to QPCR) from each group were in-
cluded (data not shown).
PCV-2 macroscopic lesion assessment, histopathological
analyses and PCV-2 immunohistochemistry (IHC) results
No relevant gross findings were observed during the nec-
ropsies. In addition, all lymphoid tissue samples analysed
scored 0 for lymphocyte depletion (LD) as well as for his-
tiocytic infiltration (HI). On the other hand, all lymphoid
tissue samples from animals included in groups NV-NC
and VS-C PCV-2 scored 0 by IHC (Table 2). The NV-C
PCV-2 group had a significantly higher number of animals
with IHC scoring ≥1 in Tracheobronchial lymph node
(TBLN) (8/14, 57.1%) than the VS-C PCV-2 group (0/15,
0%). Additionally, the number of animals with at least one
tissue with score ≥ 1 was significantly higher in the NV-C
PCV-2 group (9/14, 64.2%) when compared to VS-C
Fig. 2 PCV-2 QPCR results expressed in percentage of positive serum samples per treatment group and sampling point. Different letters in
superscript means p < 0.05
Fig. 3 Mean PCV-2 copies/mL in PCV-2 QPCR positive samples per treatment group and sampling point
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PCV-2 (0/15) and VC-C PCV-2 (2/14, 14.3%)
groups (Table 2). No significant differences on the num-
ber of lymphoid tissues scoring ≥1 between both vacci-
nated groups were detected.
Mhyo results
Detection of antibodies against Mhyo
Percentages of Mhyo seropositive animals are repre-
sented in Fig. 4. All animals included in the study were
seronegative by ELISA prior to the start of the study.
Pigs from the NV-NC group remained seronegative
through the study. In the NV-C Mhyo group, serocon-
version was observed on necropsy day in which 7 out of
the 15 animals were seropositive. In both vaccinated
groups, almost all animals were seropositive from 3
weeks post vaccination (SD21) onwards. Statistically sig-
nificant differences between both vaccinated versus both
non-vaccinated groups were observed on SD21, SD41,
SD62 and SD91 (necropsy day).
Mhyo macroscopic and microscopic compatible lung lesions
assessment
None of the animals included in the NV-NC group
showed macroscopic Mhyo compatible lung lesions (cra-
nio-ventral pulmonary consolidation, CVPC). From the 43
endotraqueally Mhyo inoculated animals (two animals
died before necropsy), 25 (58%) animals showed CVPC
(mean: 3.36; min 0.12-max 38.63). Animals from the NV-
C Mhyo group showed a significantly higher CVPC score
(Table 3) than the animals from both vaccinated groups.
From these 25 animals showing CVPC, 12 did not
show broncho-interstitial pneumonia (BIP) (10 received
a microscopic score 0 and the remaining ones were
scored 1). Therefore, macroscopic lesions observed in
these 12 animals were re-scored 0 for the gross evalu-
ation purposes. In consequence the number of animals
showing CVPC due to BIP was 13 out of 43 (30%). From
these 13, the number of animals showing CVPC was sig-
nificantly higher in the NV-C (n = 10, 77%) group than
Table 2 Number of animals with a IHC score ≥ 1 per lymphoid tissue and number of animals with at least one tissue scored ≥1 per
treatment group
Treatment Number of animals with a IHC score≥ 1 per lymphoid tissue Number of animals with at least one
tissue scored ≥1 per treatment groupTO TBLN MSLN ISLN
NV-NC 0a 0a 0 a 0 a 0a (0%)
NV-C PCV-2 5a (35.7%) 8b (57.1%) 2a (14.3%) 4a (28.6%) 9b (64.2%)
VS-C PCV-2 0a 0 a 0a 0a 0a (0%)
VC-C PCV-2 1a (7.1%) 2a, b (14.3%) 1a (7.1%) 1a (7.1%) 2a (14.2%)
Different letters in superscript within a column means p < 0.05
TO Tonsil, TBLN Tracheobronchial lymph node, MSLN Mesenteric lymph node, ISLN Superficial inguinal lymph node, LD Lymphocyte depletion, HI Histiocytic
infiltration, IHC Immunohistochemistry
Fig. 4 Percentage of M. hyopneumoniae seropositive animals per treatment and sampling point. Different superscript letters mean p < 0.05
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the ones from VS-C Mhyo (n = 2, 14%) and VC-C Mhyo
(n = 1, 7%) groups. When considered CVPC+BIP, ani-
mals from the NV-C Mhyo group showed a higher
CVPC score (Table 3) than the animals from both vacci-
nated groups (p < 0.1).
From the 13 animals showing BIP + CVPC, 10 were
microscopically scored as 3 (7 from NV-C Mhyo; 2
from VS-C Mhyo and 1 from VC-C Mhyo) and 3
were scored as 4 (all of them from NV-C
Mhyo group) (Fig. 5). The NV-C Mhyo group had a
significantly higher number of animals scoring ≥3
than the vaccinated groups. No significant differences
on the number of animals scored ≥3 between vacci-
nated groups were found.
Discussion
PCV-2 and Mhyo combined vaccination strategies (RTM
and RTU) have interested both veterinarians and farmers
for several years, since they decrease the cost of labour.
Besides the lower labour expenses, other factors such as
animal welfare (lesser number of injections and manipu-
lations) and lower risk of other pathogen transmission
(through syringes and needles) account importantly as
benefits of a single injection of two vaccine products.
In some cases, however, a suspicion of lesser effectiv-
ity of these combined products has been suggested
[15], posing doubts on their overall benefit. In fact,
these later authors attributed such questionable effi-
cacy to the variation of the epidemiology of respira-
tory diseases among farms and regions [15], claiming
about the scarcity of comparative data on single-shot
two valence vaccines.
In the present study, the efficacy of Hyogen® and Circo-
vac® when applied separately or combined (RTM) was
assessed by means of Mhyo or PCV-2 experimental
challenges.
Table 3 Total number (percentage) and mean (minimum and maximum) macroscopic score of animals showing CVPC or CVPC+BIP
per treatment group









NV-NC 0/3 (0) 0 a 0/3a (0) 0 A
NV-C Mhyo 12/15 (80) 6.23b (0.12–38.63) 10/15b (66.6) 7.26B (38.63–0.60)
VS-C Mhyo 7/14 (50) 0.62a (0.18–1.20) 2/14a (14.3) 0.75A (1.20–0.30)
VC-C Mhyo 6/14 (43) 0.84a (0.12–2.48) 1/14a (7.2) 0.53A
Different low case letters in superscript within a column mean p < 0.05; different capital letters in superscript within a column mean p < 0.1
Fig. 5 Percentage of animals showing different microscopic lung lesion score (0–4) per treatment group. NV-C had significantly higher number of
animals showing a microscopic score≥ 3 than both vaccinated groups
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The outcome of the present PCV-2 experimental in-
fection was subclinical as no PCV-2 clinical signs were
observed. These results are in line with previous PCV-2
experimental inoculations [16, 17]. In this scenario, both
PCV-2 vaccine application strategies showedhigher
PCV-2 ELISA S/P values after vaccination than the NV-
C group. Although statistically significant differences on
PCV-2 ELISA S/P values between both vaccinated
groups were seen on SD70 and SD76, both groups
reached the maximum and similar serologic values on
the necropsy day. The reason behind the fact that the
overall values at most of samplings were higher in the
VS-C-PCV-2 group compared to the VC-C-PCV-2 is
unknown. Despite it cannot be ruled out that combin-
ation of both products may exert certain deleterious ef-
fect on PCV-2 seroconversion, the virological outcome
was not significantly different among these groups. Add-
itionally, both vaccinated groups (VS-C PCV-2 and VC-
C PCV-2 groups) were able to reduce (being statistically
significant on necropsy day) the percentage of PCV-2
QPCR positive serum samples when compared to the
one of the NV-C group. Indeed, vaccinated animals (ei-
ther separately or RTM) had a numerically lower AUC
than non-vaccinated ones. This reduction of PCV-2 in-
fected pigs in both PCV-2 vaccinated groups was accom-
panied by a lower number of animals harbouring PCV-2
in tissues when compared to their non-vaccinated coun-
terparts. Moreover, results obtained in animals vacci-
nated with the PCV-2 separate application resembled
the ones obtained using the same vaccine in 3-week-old
animals under experimental PCV-2 subclinical infections
[18, 19].
On the other hand, vaccination against Mhyo, either
separately or in a RTM combination with the PCV-2
vaccine, resulted in a significantly higher percentage
of seropositive animals 3 weeks after vaccination, a
significant reduction of the number of animals show-
ing M. hyopneumoniae macro and microscopic lesions
as well as their extension (macroscopic score) and se-
verity (microscopic score) when compared to non-
vaccinated animals. Seroconversion results and the
macroscopic lung lesion reduction are in agreement
when compared with experimental inoculations in
which the same Mhyo vaccine employed in this study
was used solely [20].
Taken all together, obtained results point out that the
two vaccines used in this study (either by separate, which
represents the current licensing use, or in combination,
off-label scenario), offer similar results from virological,
immunological and pathological points of view under ex-
perimental conditions. Therefore, these data point out the
possibility of combining the abovementioned vaccine
products in one single injection in these farms where both
vaccines are applied in a similar age.
Conclusion
The present study expands the knowledge on the possibil-
ity of using two separate Mhyo and PCV-2 commercial
vaccines as a RTM product, which offered equivalent viro-
logical/immunological and pathological outcomes as com-
pared to these vaccines by separate. Next step should be




At approximately 1 week of age (WOA), blood samples
from 129 male non-castrated piglets born from PCV-2
non-vaccinated sows were obtained from a Mhyo nega-
tive farm. These blood samples were analysed for the
presence of PCV-2 by QPCR assay to rule out any posi-
tive piglets. Those QPCR PCV-2 negative samples were
tested for antibodies against Mhyo and PCV-2 using
commercial ELISAs. Then, 96 two-week old male piglets
that resulted negative to PCV-2 QPCR, with low levels
of PCV-2 antibodies (Sample/Positive (S/P) ratio ≤ 0.8 in
Ingezim Circo IgG ELISA) and seronegative against
Mhyo (percentage of inhibition > 50%) were selected and
transported to an IRTA experimental farm.
Vaccine and placebo products
The vaccine tested products were a commercial inacti-
vated PCV-2a based vaccine (CIRCOVAC®, CEVA,
France; batch number L438978 and expiration date: 03/
05/2018) with an oil/water adjuvant and a commercial
inactivated Mhyo vaccine (Hyogen®, CEVA, France;
batch number 0904FT1B and expiration date: 11/07/
2018) with oil adjuvant. Phosphate-buffered saline (PBS)
(Lonza, Spain; batch number 7MB052 and expiration
date: 03/2019) was used as placebo.
Inoculum
PCV-2 strain Sp-10-7-54-13 (PCV-2b genotype) was
used as PCV-2 inoculum [21]. This strain was isolated
from the lymphoid tissues of a field case of PCVDs in
2006 in Spain. The inoculum preparation and the post-
challenge titration were as described previously [21].
A fresh culture of Mhyo field strain 281 was used as
Mhyo inoculum. This strain was isolated in 2006 from a
lung of a slaughtered Spanish pig showing CVPC. The
inoculum preparation and the post-challenge titration
were as described previously [22]. Absence of M. hyorhi-
nis and M. hyosynoviae was confirmed by specific PCR.
Experimental design and samplings
Upon arrival at the experimental facilities (SD-5), 96 ani-
mals were distributed in different groups (Table 4) ac-
cording to the body weight. The 45 pigs with the lowest
S/P PCV-2 values at 1 WOA were distributed in the 3
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groups of the PCV-2 study. Similarly, 45 animals were
randomly included in the Mhyo study and distributed in
3 groups. The 6 remaining pigs were included in the
NV-NC group. Animals of different treatment groups
were allocated in different pens and rooms.
At approximately 21 ± 3 days of age (3 WOA), animals
from non-vaccinated (NV) groups (NV-NC [non-chal-
lenged], NV-C PCV-2 [challenged with PCV-2] and NV-C
Mhyo [challenged with Mhyo]) were injected intramuscu-
larly with 2.5mL of phosphate-buffered saline (PBS) at the
left side of the neck. Animals from group VS (separated
vaccination)-C PCV-2 and VS-C Mhyo were intramuscu-
larly vaccinated, following manufacturer’s instructions
with 0.5 mL of Circovac® and with 2mL of Hyogen® at the
left and right side of the neck, respectively. Animals from
group VC (combined vaccination)-C PCV-2 and VC-C
Mhyo were intramuscularly vaccinated with 2.5mL of a
RTM combined vaccine (Circovac® + Hyogen®) at the left
side of the neck. The RTM vaccine was prepared as fol-
lows: first Circovac® was re-constituted as per manufac-
turer’s instructions and then 10mL of Circovac® were
mixed with 40mL of Hyogen® in a sterile container.
At SD62 (approximately 12 WOA) animals were
weighted, sampled and challenged as follows: NV-NC pigs
were challenged with PBS (3mL intranasally in three of
them and 5mL endotracheally in the other three); animals
from C PCV-2 groups were intranasally challenged with 3
mL of inoculum 105.4 TCID50/mL of PCV-2b strain Sp-
10-7-54-13; and, finally, animals from C Mhyo groups
were endotracheally challenged with 5mL per day of 107.5
(first day) and 108 (second day) PCR50/mL fresh culture of
a Mhyo isolate on two consecutive days. PCV-2 intranasal
inoculation was performed as described elsewhere [21].
Mhyo endotracheal inoculation was done as reported pre-
viously [22].
After inoculation, pigs were clinically examined on a
daily basis focused on respiratory signs such as dyspnoea
and coughing. Observations consisted of pen-side visual
assessment of animals by experienced animal care-takers.
At SD83 (21 days post PCV-2 challenge), the 3 piglets
mock-challenged by intranasal route from group NV-NC
and all pigs from PCV-2 groups were humanely euthanized
with an overdose of sodium pentobarbital. At necropsy, ani-
mals were firstly bled and weighted and then different tis-
sue samples (tonsils, tracheobronchial lymph nodes,
mesenteric lymph nodes and superficial inguinal lymph
nodes) were collected. At SD91 (28 days post-Mhyo chal-
lenge) the 3 remaining piglets from group NV-NC and all
pigs from Mhyo groups were bled, weighted and eutha-
nized as explained before. At necropsy and subsequent
pathological analyses, lungs were scored in a blinded fash-
ion for gross and microscopic lesions related to Mhyo
infection.
The study procedure was referenced 9998 by Animal
Experimentation Ethics Committee of the Generalitat de
Catalunya (Departament de Territori i Sostenibilitat,
Direcció General de Polítiques Ambientals i Medi
Natural).
Samples
Blood samples were collected individually from all pig-
lets, at the source farm, prior to the start of the study for
screening and inclusion purposes (SD-14), at SD0 (vac-
cination day) and then every 3 weeks post-vaccination
(SD21 and SD41). For PCV-2 challenged animals, sam-
ples were taken on the day before challenge (SD62),
SD70, SD76 and SD83 (necropsy). For Mhyo challenged
animals, samples were collected on the day before chal-
lenge SD62 and at necropsy on SD91.
Samples were transferred to the laboratory site at 4–
8 °C. Blood samples were centrifuged and serum was ob-
tained. Until use, sera were stored at − 20°C. The period
between blood sampling and storage did not exceed 24 h.
Table 4 Experimental design of the study
Treatment N Vaccination Challenge Necropsy PCV-2 Necropsy Mhyo
Left Side of the Neck (volume and
route)
Right Side of the
Neck
(volume and route)
NV-NC 6 PBS (2.5 mL IM) – PBS PCV-2 lesion assessment Mhyo lung lesion scoring
NV-C/PCV-2 15 PBS (2.5 mL IM) – PCV-2b PCV-2 lesion assessment –
VS-C/PCV-2 15 Circovac (0.5 mL IM) Hyogen (2.0 mL IM) PCV-2b –
VC-C/PCV-2 15 Circovac + Hyogen (2.5 mL IM RTM) – PCV-2b –
NV-C/Mhyo 15 PBS (2.5 mL IM) – Mhyo – Mhyo Lung lesion scoring
VS-C/Mhyo 15 Circovac (0.5 mL IM) Hyogen (2.0 mL IM) Mhyo –
VC-C/Mhyo 15 Circovac + Hyogen (2.5 mL IM RTM) – Mhyo –
NV-NC Non-vaccinated Non-challenged, NV-C Non-vaccinated-Challenged animals, VS-C Challenged (with PCV2 or Mhyo) Separate vaccination, VC-C (with PCV2 or
Mhyo) Combined (RTM) vaccination
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Post-mortem examination
Mhyo lung lesion scoring
At necropsy, photographs were taken from both sides of
the lung. Afterwards, extension of Mhyo-compatible
lung lesions (CVPC) were assessed according to the
score recommended for the European Pharmacopoeia
(Ph. Eur. monograph no.2448). Briefly, for each lung,
each individual lobe was assessed as percentage of lung
with lesions resulting from the Mhyo challenge. After-
wards, the proportion of affected lung area was multi-
plied by the relative weight of each lobe [22]. In
addition, lung samples from pneumonic areas were col-
lected and fixed by immersion in 10% buffered formalin
for histopathological examination. Fixed tissue samples
were dehydrated and embedded in paraffin blocks, stained
with haematoxylin-eosin stain, and examined for lesions
suggestive of Mhyo infection. Mhyo lung lesion scoring was
performed in a blinded fashion taking into account two
pathological criteria: (1) presence of gross CVPC and (2)
confirmation of such gross lesions as BIP, as previously de-
scribed [16]. Absence of lesion was scored 0; lesions charac-
terized by inflammation non-suggestive of enzootic
pneumonia were scored 1 and 2; scores 3 and 4 were con-
sidered suggestive of Mhyo infection. Score 3 consisted of
lesions with perivascular and peribronchiolar lymphoplas-
macytic hyperplasia, pneumocyte type II hyperplasia and
oedema fluid in the alveolar spaces with neutrophils, mac-
rophages and plasma cells. Score 4 was considered when le-
sions with the characteristics of score 3 together with the
presence of evident peribronchial and perivascular lymph-
oid follicles were observed. Scores 3 and 4 were considered
highly compatible with lesions of Mhyo infection. There-
fore, overall Mhyo-like lesions were evaluated for the exist-
ence of EP-like gross lesions and the score was kept only if
histopathological evaluation confirmed the presence of BIP.
Those cases showing EP-like gross lesions, but with micro-
scopic evidence only of pulmonary collapse (atelectasis)
were scored as 0 on the gross evaluation.
Histopathologic studies and PCV-2 immunohistochemistry
Tonsil and tracheo-bronchial, mesenteric and inguinal
superficial lymph nodes were fixed by immersion in 10%
buffered formalin, dehydrated and embedded in paraffin
blocks (one block per pig with all four tissues). From each
paraffin block, two consecutive 4 μm thick sections were
cut. One section was stained with the haematoxylin-eosin
(HE) stain and examined for lesions compatible with
PCV-2 infection, including lymphocyte depletion (LD)
and histiocytic infiltration (HI). The other section was
processed for immunohistochemistry (IHC) for PCV-2
antigen detection. Lymphocyte depletion, histiocytic infil-
tration and the amount of PCV-2 antigen were scored
from 0 (no lesions/no staining) to 3 (severe lesions/wide-
spread antigen distribution). The score for each lymphoid
tissue sample was calculated as follows: score for lympho-
cyte depletion plus score for histiocytic infiltration plus
score for IHC. Afterwards, a global histopathological score
per pig was calculated by summing the individual scores
of all four lymphoid tissue samples [23].
Detection of antibodies against PCV-2
Presence of antibodies against PCV-2 in blood were
tested with the commercial ELISA Ingezim Circo IgG
11. PCV.K1 kit (Ingenasa, Madrid, Spain). Results were
expressed as mean S/P values.
Detection of antibodies against Mhyo
Presence of antibodies against Mhyo in serum samples
were tested with the commercial competitive
ELISA IDEIA M.hyopneumoniae, EIA kit (ThermoFisher
Scientific. Hampshire, UK). Results were expressed as
percentage of positive samples (percentage of inhibition
[PI] < 50%).
Detection and quantification of PCV-2 DNA
DNA was extracted from 200 μL of serum by using the
MagMAX™ Pathogen RNA/DNA Kit (Thermo Fischer
Scientific Baltics. Vilnius, Lithuania) following the manu-
facturer’s instructions. The DNA obtained was sus-
pended in 90 μL of elution solution. The commercial
QPCR kit VetMAX™ Porcine PCV2 Quant Kit (Applied
Biosystems, Lisseu, France) was used to detect and quan-
tify PCV-2 DNA in serum samples. PCV-2 QPCR were
expressed as percentage of QPCR positive samples (in-
cluding also the samples QPCR positive but below limit
of quantification) and mean PCV-2 copies/mL of serum
(including only the samples within the range of quantifi-
cation). The AUC of the PCV-2 load during the post-
challenge period (from SD70 to SD86) per treatment
group was calculated following the trapezoidal rule [24].
Statistical analyses
To compare baseline characteristics between groups
(PCV-2 S/P ELISA values at 1 WOA and body weight at
arrival day [SD-5]) ANOVA was performed.
Two independent statistical analyses (one per each chal-
lenge experiment) were performed. In each analysis, com-
parison between the NV-NC, NV-C and both V (separated
vs combined) groups were done. These comparisons were
conducted considering all 6 NV-NC animals for all sam-
plings but SD91 (necropsy day for Mhyo) in which only 3
animals remained (the other three were necropsied on
SD84, when PCV-2 challenged pigs were euthanized).
Average daily weight gain between SD-5 to SD62, SD-5
to SD91 and SD62 to SD91 was calculated for each treat-
ment group. The analysis of quantitative variables (PCV-2
ELISA values, body weight, ADWG, QPCR, AUC and
macroscopic lung score) was performed using an ANOVA
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or Kruskal-Wallis test. For categorical variables (percent-
age of positivity by Mhyo ELISA, percentage of positivity
by PCV-2 QPCR, microscopic Mhyo score and PCV-2
IHC and CVPC presence), the Chi square test or likeli-
hood ratio test were used. For the analysis of total PCV-2
IHC score, a logistic regression model was used. Pairwise
comparisons were corrected for multiplicity of contrasts.
Additionally, each response variable was analysed using
linear mixed models. Sow was included as a random ef-
fect, and group and variables that had lack of homogeneity
between groups as fixed effects. A normal distribution was
considered for the analysis of ELISA and body weight, a
Binary distribution for the analysis of microscopic scores
and a Poisson distribution for the analysis of macroscopic
scores.
All analyses were performed with software SAS v9.4
(SAS Institute Inc., Cary, NC, USA). The significance
level was set at p < 0.05.
Abbreviations
Mhyo: Mycoplasma hyopneumoniae; PCV-2: Porcine circovirus 2; RTM: Ready-
to-mix; RTU: Ready-to-use; WOA: Weeks of age; NV: Non-vaccinated;
V: Vaccinated; NC: Non-challenged; VC: Combined vaccination; VS: Separate
vaccination; ADWG: Average daily weight gain; QPCR: Quantitative
Polymerase Chain Reaction; ELISA: Enzyme-linked immunosorbent assay; S/
P: Sample/Positive; PI: Percentage of Inhibition; PBS: Phosphate-buffered
saline; CVPC: Cranio-ventral pulmonary consolidation; BIP: Broncho-interstitial
pneumonia; HE: Haematoxylin-eosin; LD: Lymphocyte depletion;
HI: Histiocytic infiltration; IHC: Immunohistochemistry
Acknowledgments
The authors would like to acknowledge the personnel from IRTA-Monells fa-
cilities and CERCA Programme/Generalitat de Catalunya.
Authors’ contributions
MS, GG, RK and JS conceived and designed the study. GG and MS drafted
the manuscript and coordinated the study execution and sample processing.
RC, PP, DP, CL contributed to the sampling and study execution. AP and A Ll
prepared the inoculums. EH, ALl, and MP processed all the samples
collected. OV performed the statistical analyses. JS and RK revised the
manuscript. All the authors read and approved the final manuscript.
Funding
This study was funded by CEVA through the contract n°: A4170 with IRTA-
CReSA.
Availability of data and materials
The datasets used and analyzed during the trial are available from the
corresponding author on request.
Ethics approval and consent to participate
The study procedure was referenced 9998 by Animal Experimentation Ethics
Committee of the Generalitat de Catalunya (Departament de Territori i
Sostenibilitat, Direcció General de Polítiques Ambientals i Medi Natural).
Consent for publication
All authors agree with the content of the manuscript.
Competing interests
The authors declare that they have no competing interests. R. Krejci is
employee of CEVA.
Author details
1IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA- UAB), Campus de
la Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
2OIE Collaborating Centre for the Research and Control of Emerging and
Re-emerging Swine Diseases in Europe (IRTA-CReSA), Bellaterra, Barcelona,
Spain. 3Servei d’Estadística Aplicada, Universitat Autònoma de Barcelona,
Campus de la Universitat Autònoma de Barcelona, Bellaterra, 08193
Barcelona, Spain. 4Departament de Sanitat i Anatomia Animals, Universitat
Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain. 5Ceva, La
Ballastiere-BP, 126, 33501 Libourne Cedex, France. 6UAB, Centre de Recerca
en Sanitat Animal (CReSA, IRTA- UAB), Campus de la Universitat Autònoma
de Barcelona, Bellaterra, 08193 Barcelona, Spain.
Received: 27 December 2019 Accepted: 4 March 2020
References
1. Fablet C, Rose N, Grasland B, Robert N, Lewandowski E, Gosselin M. Factors
associated with the growing-finishing performances of swine herds: an exploratory
study on serological and herd level indicators. Porcine Health Manag. 2018;4:6.
2. Alarcon P, Rushton J, Wieland B. Cost of post-weaning multi-systemic
wasting syndrome and porcine circovirus type-2 subclinical infection in
England - an economic disease model. Prev Vet Med. 2013;110(2):88–102.
3. Segales J. Porcine circovirus type 2 (PCV2) infections: clinical signs,
pathology and laboratory diagnosis. Virus Res. 2012;164(1–2):10–9.
4. Chae C. Porcine respiratory disease complex: interaction of vaccination and
porcine circovirus type 2, porcine reproductive and respiratory syndrome
virus, and Mycoplasma hyopneumoniae. Vet J. 2016;212:1–6.
5. Dee S. The porcine respiratory disease complex: are subpopulations
important? Swine Health Prod. 1996;4(3):147–9.
6. Opriessnig T, Gimenez-Lirola LG, Halbur PG. Polymicrobial respiratory
disease in pigs. Anim Health Res Rev. 2011;12(2):133–48.
7. Opriessnig T, Thacker EL, Yu S, Fenaux M, Meng XJ, Halbur PG. Experimental
reproduction of postweaning multisystemic wasting syndrome in pigs by
dual infection with Mycoplasma hyopneumoniae and porcine circovirus type
2. Vet Pathol. 2004;41(6):624–40.
8. Opriessnig T, Madson DM, Schalk S, Brockmeier S, Shen HG, Beach NM, et al.
Porcine circovirus type 2 (PCV2) vaccination is effective in reducing disease
and PCV2 shedding in semen of boars concurrently infected with PCV2 and
Mycoplasma hyopneumoniae. Theriogenology. 2011;76(2):351–60.
9. Maes D, Sibila M, Kuhnert P, Segales J, Haesebrouck F, Pieters M. Update on
Mycoplasma hyopneumoniae infections in pigs: knowledge gaps for
improved disease control. Transb Emerg Dis. 2018;65(Suppl 1):110–24.
10. Garza-Moreno L, Segales J, Pieters M, Romagosa A, Sibila M. Acclimation
strategies in gilts to control Mycoplasma hyopneumoniae infection. Vet
Microbiol. 2018;219:23–9.
11. Segales J. Best practice and future challenges for vaccination against
porcine circovirus type 2. Expert Rev Vaccines. 2015;14(3):473–87.
12. Hernandez-Caravaca I, Gourgues SF, Rodriguez V, Estrada ED, Ceron JJ,
Escribano D. Serum acute phase response induced by different vaccination
protocols against circovirus type 2 and Mycoplasma hyopneumoniae in
piglets. Res Vet Sci. 2017;114:69–73.
13. Tzika ED, Tassis PD, Koulialis D, Papatsiros VG, Nell T, Brellou G, et al. Field
efficacy study of a novel ready-to-use vaccine against Mycoplasma
hyopneumoniae and porcine circovirus type 2 in a Greek farm. Porcine
Health Manag. 2015;1:15.
14. Park C, Kang I, Seo HW, Jeong J, Choi K, Chae C. Comparison of 2 commercial
single-dose Mycoplasma hyopneumoniae vaccines and porcine reproductive
and respiratory syndrome virus (PRRSV) vaccines on pigs dually infected with
M. hyopneumoniae and PRRSV. Can J Vet Res. 2016;80(2):112–23.
15. Kaalberg L, Geurts V, Jolie R. A field efficacy and safety trial in the
Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use
porcine circovirus type 2 and Mycoplasma hyopneumoniae combined
vaccine. Porcine Health Manag. 2017;3:23.
16. Sibila M, Fort M, Nofrarias M, Perez de Rozas A, Galindo-Cardiel I, Mateu E,
et al. Simultaneous porcine circovirus type 2 and Mycoplasma
hyopneumoniae co-inoculation does not potentiate disease in conventional
pigs. J Comp Pathol. 2012;147(2–3):285–95.
17. Opriessnig T, Prickett JR, Madson DM, Shen HG, Juhan NM, Pogranichniy RR,
et al. Porcine circovirus type 2 (PCV2)-infection and re-inoculation with
homologous or heterologous strains: virological, serological, pathological
and clinical effects in growing pigs. Vet Res. 2010;41(3):31.
18. Opriessnig T, Xiao CT, Halbur PG, Gerber PF, Matzinger SR, Meng XJ. A
commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d
Sibila et al. Porcine Health Management            (2020) 6:11 Page 10 of 11
viremia and shedding and prevents PCV2d transmission to naive pigs under
experimental conditions. Vaccine. 2017;35(2):248–54.
19. Opriessnig T, Patterson AR, Madson DM, Pal N, Ramamoorthy S, Meng XJ,
et al. Comparison of the effectiveness of passive (dam) versus active (piglet)
immunization against porcine circovirus type 2 (PCV2) and impact of
passively derived PCV2 vaccine-induced immunity on vaccination. Vet
Microbiol. 2010;142(3–4):177–83.
20. Michiels A, Arsenakis I, Boyen F, Krejci R, Haesebrouck F, Maes D. Efficacy of
one dose vaccination against experimental infection with two Mycoplasma
hyopneumoniae strains. BMC Vet Res. 2017;13(1):274.
21. Fort M, Sibila M, Nofrarias M, Perez-Martin E, Olvera A, Mateu E, et al.
Porcine circovirus type 2 (PCV2) Cap and Rep proteins are involved in the
development of cell-mediated immunity upon PCV2 infection. Vet Immunol
Immunopathol. 2010;137(3–4):226–34.
22. Garcia-Morante B, Segales J, Lopez-Soria S, de Rozas AP, Maiti H, Coll T, et al.
Induction of mycoplasmal pneumonia in experimentally infected pigs by
means of different inoculation routes. Vet Res. 2016;47(1):54.
23. Grau-Roma L, Hjulsager CK, Sibila M, Kristensen CS, Lopez-Soria S, Enoe C, et al.
Infection, excretion and seroconversion dynamics of porcine circovirus type 2
(PCV2) in pigs from post-weaning multisystemic wasting syndrome (PMWS)
affected farms in Spain and Denmark. Vet Microbiol. 2009;135(3–4):272–82.
24. Lopez-Soria S, Sibila M, Nofrarias M, Calsamiglia M, Manzanilla EG, Ramirez-
Mendoza H, et al. Effect of porcine circovirus type 2 (PCV2) load in serum
on average daily weight gain during the postweaning period. Vet Microbiol.
2014;174(3–4):296–301.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sibila et al. Porcine Health Management            (2020) 6:11 Page 11 of 11
